查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494902

到 2030 年放射性皮膚炎市場預測：按產品、階段、分銷管道和地區進行的全球分析

Radiodermatitis Market Forecasts to 2030 - Global Analysis By Product (Topical, Oral Drugs and Dressings), Stage (Mild, Moderate and Severe), Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球放射性皮膚炎市場規模為 4.583 億美元，預計到 2030 年將達到 6.284 億美元，預測期內年複合成長率為 5.4%。

放射性皮膚炎是一種由放射線治療引起的皮膚病，常見於癌症患者。症狀包括皮膚發紅、發炎、脫皮，有時甚至潰瘍。嚴重程度從輕度到重度不等，會影響生活品質並中斷癌症治療。有效的治療包括局部治療、敷料和減輕症狀的預防措施。

根據美國國家癌症美國(NCI) 的數據，約 95% 接受放射線治療的患者會出現放射性皮膚炎。

癌症增加

癌症發生率的增加是放射性皮膚炎市場的關鍵促進因素。癌症是全世界死亡的主要原因，放射治療作為重要治療方法的使用正在增加。隨著越來越多的人接受各種癌症的放射線治療，常見副作用放射性皮膚炎的盛行率也增加。對放射性皮膚炎管理解決方案（包括皮膚護膚產品和治療）的需求不斷成長，正在推動市場成長並推動該領域的創新和投資。

治療費用高

與治療放射性皮膚炎相關的費用，包括藥物、護膚產品和支持性護理，給患者帶來了經濟負擔。此外，放射治療的累積費用也加劇了經濟負擔。對許多患者來說，支付治療費用的能力是一個關鍵問題，尤其是那些保險不足或經濟拮据的患者。這種障礙可能會限制獲得最佳治療和遵守治療方法，從而影響患者的整體治療結果和市場成長。

醫療基礎設施的成長

特別是在新興國家，醫療保健設施的改善正在改善放射性皮膚炎患者獲得診斷、治療和支持性護理的機會。隨著專科診所、放射腫瘤中心、皮膚科的開設，放射性皮膚炎患者可以得到及時、全面的治療。此外，增強的基礎設施將促進研究和開發活動，並促進創新治療方法和護膚產品的推出，最終推動市場成長並改善患者的治療效果。

替代療法

替代療法對放射性皮膚炎市場構成威脅，因為它們提供自然和非藥物治療來控制放射治療與皮膚相關的副作用。從草藥療法到同類療法療法，這些治療方法可能會吸引尋求更溫和、更全面的方法的患者。因此，它可能會轉移人們對傳統醫療干涉措施和藥物的注意力和需求，從而影響競爭力和市場成長。

COVID-19 的影響：

COVID-19 大流行擾亂了醫療保健服務、推遲了非緊急治療並將重點轉移到了病毒控制上，從而影響了放射性皮膚炎市場。這導致放射性皮膚炎的診斷和治療暫時放緩。然而，一旦醫療保健系統穩定並優先考慮癌症治療，由於被壓抑的需求和放射性皮膚炎治療的持續進步，市場預計將復甦。

在預測期內，外用藥物領域預計將是最大的。

在預測期內，局部用藥預計將成為放射性皮膚炎市場中最大的部分。這一成長是由多種因素推動的，包括局部治療的便利性、使用的簡便性以及管理放射性皮膚炎症狀的有效性。此外，局部製劑的進步，包括新型化合物和遞送系統的開發，正在提高治療效果。隨著對患者舒適度和用藥依從性的日益關注，預計未來幾年對局部治療的需求將顯著成長。

線上藥局領域預計在預測期內年複合成長率最高

預計線上藥局領域在預測期內將見證放射性皮膚炎市場的良好成長。這種快速成長的主要驅動力是擴大採用電子商務平台購買藥品。便利性、可近性和廣泛的產品選擇等因素促進了這一領域的快速成長。此外，遠端醫療和數位醫療服務的趨勢進一步推動了透過線上藥局治療放射性皮膚炎的需求，推動市場擴張。

佔比最大的地區：

由於亞太地區人口眾多、感染疾病流行率不斷上升以及人們對疫苗接種益處的認知不斷提高，預計亞太地區將佔據疫苗佐劑市場的最高市場佔有率。此外，政府措施、對醫療基礎設施的投資、主要市場參與者的存在以及不斷擴大的生物製藥產業都有助於市場成長。亞太地區對創新研發的關注和有利的法規環境進一步推動了該地區的需求。

年複合成長率最高的地區：

預計在預測期內，亞太地區的放射性皮膚炎市場年複合成長率最高。這項預測是由於多種因素造成的，包括癌症發生率上升、放射線治療採用率增加、醫療基礎設施擴大以及對放射性皮膚炎管理認知的提高。此外，醫療保健技術的進步和政府改善癌症治療的舉措預計將推動該地區的市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球放射性皮膚炎市場：依產品

  • 外用
    • 皮質類固醇
    • 親水霜
    • 外用抗生素
    • 其他外用藥物
  • 口腔醫學
  • 敷料
    • 紗布浸入蜂蜜中
    • 親水膠體敷料
    • 水凝膠敷料
    • 防刺膜
    • 矽膠塗層敷料
    • 其他敷料

第6章全球放射性皮膚炎市場：依階段

  • 溫和的
  • 中等的
  • 嚴重

第7章全球放射性皮膚炎市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章全球放射性皮膚炎市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司概況

  • 3M Company
  • Acelity LP Inc.
  • Alliqua Biomedical, Inc.
  • B. Braun Melsungen AG
  • BMG Pharma SpA
  • Cardinal Health, Inc.
  • Coloplast A/S
  • Convatec Group Plc
  • DermaRite Industries, LLC
  • GlaxoSmithKline plc
  • Hollister Incorporated
  • Integra Lifesciences Holdings Corporation
  • Medline Industries, Inc.
  • MiMedx Group, Inc.
  • Molnlycke Health Care AB
  • Pfizer Inc.
  • Radiation Products Design Inc.
  • Smith & Nephew plc
  • Stratpharma AG
Product Code: SMRC26422

According to Stratistics MRC, the Global Radiodermatitis Market is accounted for $458.3 million in 2024 and is expected to reach $628.4 million by 2030 growing at a CAGR of 5.4% during the forecast period. Radiodermatitis is a skin condition caused by radiation therapy, commonly experienced by cancer patients. It manifests as redness, irritation, peeling, and sometimes ulceration of the skin. The severity ranges from mild to severe, impacting the quality of life and potentially disrupting cancer treatment. Effective management includes topical treatments, dressings, and preventive measures to mitigate symptoms.

According to the National Cancer Institute (NCI), radiation dermatitis occurs in approximately 95% of patients receiving radiation therapy.

Market Dynamics:

Driver:

Increasing incidence of cancer

The increasing incidence of cancer serves as a significant driver in the radiodermatitis market. With cancer being a leading cause of mortality worldwide, the utilization of radiation therapy as a crucial treatment modality is rising. As more individuals undergo radiation therapy for various cancer types, the prevalence of radiodermatitis, a common side effect, also escalates. This heightened demand for radiodermatitis management solutions, including skincare products and treatments, propels market growth, driving innovation and investment in this sector.

Restraint:

High treatment costs

The expenses associated with managing radiodermatitis, including medications, skincare products, and supportive care, impose a financial burden on patients. Additionally, the cumulative costs of radiation therapy sessions exacerbate the economic strain. For many patients, especially those without adequate insurance coverage or financial resources, the affordability of treatments becomes a significant concern. This barrier may limit access to optimal care and adherence to treatment regimens, impacting overall patient outcomes and market growth.

Opportunity:

Growing healthcare infrastructure

Improved healthcare facilities, particularly in emerging economies, enhance access to diagnosis, treatment, and supportive care for radiodermatitis patients. With the establishment of specialized clinics, radiation oncology centers, and dermatology services, individuals can receive timely and comprehensive management for radiodermatitis. Moreover, enhanced infrastructure fosters research and development activities, facilitating the introduction of innovative treatment modalities and skincare products, ultimately driving market growth and improving patient outcomes.

Threat:

Alternative therapies

Alternative therapies pose a threat to the radiodermatitis market as they offer perceived natural or non-pharmaceutical remedies for managing skin-related side effects of radiation therapy. These therapies, ranging from herbal remedies to homeopathic treatments, may attract patients seeking gentler or more holistic approaches. Consequently, they can divert attention and demand away from conventional medical interventions and pharmaceutical products, impacting their competitiveness and market growth.

Covid-19 Impact:

The COVID-19 pandemic has impacted the radiodermatitis market by disrupting healthcare services, delaying non-urgent treatments, and shifting focus towards managing the virus. This has led to a temporary slowdown in radiodermatitis diagnosis and treatment procedures. However, as healthcare systems stabilize and prioritize cancer care, the market is expected to rebound, driven by pent-up demand and ongoing advancements in radiodermatitis management.

The topical segment is expected to be the largest during the forecast period

During the forecast period, the topical segment is poised to emerge as the largest in the radiodermatitis market. This prominence is fueled by various factors, such as the convenience of topical treatments, their ease of application, and their effectiveness in managing radiodermatitis symptoms. Moreover, advancements in topical formulations, including the development of novel compounds and delivery systems, are enhancing their therapeutic efficacy. With an increasing focus on patient comfort and adherence, the demand for topical treatments is expected to witness substantial growth in the coming years.

The online pharmacy segment is expected to have the highest CAGR during the forecast period

The online pharmacy segment is forecasted to experience lucrative growth in the radiodermatitis market during the projected period. This surge is primarily driven by the increasing adoption of e-commerce platforms for purchasing pharmaceutical products. Factors such as convenience, accessibility, and a wide range of product options contribute to the segment's rapid growth. Additionally, the growing trend of telemedicine and digital healthcare services further propels the demand for radiodermatitis treatments through online pharmacies, fostering market expansion.

Region with largest share:

The Asia Pacific is projected to hold the highest market share in the vaccine adjuvant market due to its large population, increasing prevalence of infectious diseases, and rising awareness about vaccination benefits. Additionally, government initiatives and investments in healthcare infrastructure, coupled with the presence of key market players and an expanding biopharmaceutical industry, contribute to market growth. The region's focus on innovative research and development, along with favorable regulatory environments, further drives the demand in Asia Pacific region.

Region with highest CAGR:

The Asia Pacific region is anticipated to exhibit the highest CAGR in the radiodermatitis market over the forecast period. This projection is attributed to several factors, including rising cancer incidence, increased adoption of radiation therapy, expanding healthcare infrastructure, and growing awareness about radiodermatitis management. Additionally, advancements in healthcare technology and government initiatives to improve cancer care are expected to drive market growth in this region.

Key players in the market

Some of the key players in Radiodermatitis Market include 3M Company, Acelity L.P. Inc., Alliqua Biomedical, Inc., B. Braun Melsungen AG, BMG Pharma S.p.A., Cardinal Health, Inc., Coloplast A/S, Convatec Group Plc, DermaRite Industries, LLC, GlaxoSmithKline plc, Hollister Incorporated, Integra Lifesciences Holdings Corporation, Medline Industries, Inc., MiMedx Group, Inc., Molnlycke Health Care AB, Pfizer Inc., Radiation Products Design Inc., Smith & Nephew plc, and Stratpharma AG.

Key Developments:

In May 2024, 3M has cut the ribbon on a new 90,000-square-foot expansion at the company's facility in Valley, Nebraska that will increase the plant's manufacturing capacity and add new jobs to the community. The $67 million investment includes new production lines, equipment and a warehouse, and will help 3M more quickly meet customer demand for the company's personal safety products. The expansion of the plant is expected to create about 40 new jobs.

In January 2024, Cardinal Health announced that it has entered into a definitive agreement to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization for $1.2B in cash. Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology.

Products Covered:

  • Topical
  • Oral Drugs
  • Dressings

Stages Covered:

  • Mild
  • Moderate
  • Severe

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Radiodermatitis Market, By Product

  • 5.1 Introduction
  • 5.2 Topical
    • 5.2.1 Corticosteroids
    • 5.2.2 Hydrophilic Creams
    • 5.2.3 Topical Antibiotics
    • 5.2.4 Other Topicals
  • 5.3 Oral Drugs
  • 5.4 Dressings
    • 5.4.1 Honey Impregnated Gauze
    • 5.4.2 Hydrocolloid Dressings
    • 5.4.3 Hydrogel Dressings
    • 5.4.4 No Sting Barrier Film
    • 5.4.5 Silicone Coated Dressings
    • 5.4.6 Other Dressings

6 Global Radiodermatitis Market, By Stage

  • 6.1 Introduction
  • 6.2 Mild
  • 6.3 Moderate
  • 6.4 Severe

7 Global Radiodermatitis Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Radiodermatitis Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 3M Company
  • 10.2 Acelity L.P. Inc.
  • 10.3 Alliqua Biomedical, Inc.
  • 10.4 B. Braun Melsungen AG
  • 10.5 BMG Pharma S.p.A.
  • 10.6 Cardinal Health, Inc.
  • 10.7 Coloplast A/S
  • 10.8 Convatec Group Plc
  • 10.9 DermaRite Industries, LLC
  • 10.10 GlaxoSmithKline plc
  • 10.11 Hollister Incorporated
  • 10.12 Integra Lifesciences Holdings Corporation
  • 10.13 Medline Industries, Inc.
  • 10.14 MiMedx Group, Inc.
  • 10.15 Molnlycke Health Care AB
  • 10.16 Pfizer Inc.
  • 10.17 Radiation Products Design Inc.
  • 10.18 Smith & Nephew plc
  • 10.19 Stratpharma AG

List of Tables

  • Table 1 Global Radiodermatitis Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Radiodermatitis Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Radiodermatitis Market Outlook, By Topical (2022-2030) ($MN)
  • Table 4 Global Radiodermatitis Market Outlook, By Corticosteroids (2022-2030) ($MN)
  • Table 5 Global Radiodermatitis Market Outlook, By Hydrophilic Creams (2022-2030) ($MN)
  • Table 6 Global Radiodermatitis Market Outlook, By Topical Antibiotics (2022-2030) ($MN)
  • Table 7 Global Radiodermatitis Market Outlook, By Other Topicals (2022-2030) ($MN)
  • Table 8 Global Radiodermatitis Market Outlook, By Oral Drugs (2022-2030) ($MN)
  • Table 9 Global Radiodermatitis Market Outlook, By Dressings (2022-2030) ($MN)
  • Table 10 Global Radiodermatitis Market Outlook, By Honey Impregnated Gauze (2022-2030) ($MN)
  • Table 11 Global Radiodermatitis Market Outlook, By Hydrocolloid Dressings (2022-2030) ($MN)
  • Table 12 Global Radiodermatitis Market Outlook, By Hydrogel Dressings (2022-2030) ($MN)
  • Table 13 Global Radiodermatitis Market Outlook, By No Sting Barrier Film (2022-2030) ($MN)
  • Table 14 Global Radiodermatitis Market Outlook, By Silicone Coated Dressings (2022-2030) ($MN)
  • Table 15 Global Radiodermatitis Market Outlook, By Other Dressings (2022-2030) ($MN)
  • Table 16 Global Radiodermatitis Market Outlook, By Stage (2022-2030) ($MN)
  • Table 17 Global Radiodermatitis Market Outlook, By Mild (2022-2030) ($MN)
  • Table 18 Global Radiodermatitis Market Outlook, By Moderate (2022-2030) ($MN)
  • Table 19 Global Radiodermatitis Market Outlook, By Severe (2022-2030) ($MN)
  • Table 20 Global Radiodermatitis Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 21 Global Radiodermatitis Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 22 Global Radiodermatitis Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 23 Global Radiodermatitis Market Outlook, By Online Pharmacies (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.